Compare Adaptive Biotechnologies Corp (ADPT) vs Mattel Inc (MAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Mattel Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20 (market cap $3.33B), while Mattel Inc trades at $13.17 (market cap $3.90B). The key difference: Mattel Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | MAT | |
|---|---|---|
Market Cap | $3.33B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $22.16 |
52-Week Low | $10.24 | $13.05 |
Enterprise Value | $3.19B | $5.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Mattel (MAT) trades at $13.42, up 0.6% on the day, with a bearish technical signal but bullish oscillators like RSI suggesting potential oversold conditions. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results pending. Financially, it maintains solid profitability with a 9.27% net margin and attractive valuation ratios, including a P/E of 8.36. Recent news highlights brand expansions and a shareholder push for strategic alternatives.
The outlook is cautiously optimistic, supported by strong brand portfolio and analyst consensus, but risks include declining cash flows and competitive pressures. Investment opportunities lie in potential strategic moves and undervaluation, while key risks involve execution challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
